Apollo Endosurgery, Inc. (NASDAQ:APEN) major shareholder Stonepine Capital, L.P. acquired 5,287 shares of the company’s stock in a transaction on Tuesday, December 26th. The shares were bought at an average cost of $5.00 per share, with a total value of $26,435.00. Following the acquisition, the insider now directly owns 2,555,151 shares in the company, valued at $12,775,755. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Stonepine Capital, L.P. also recently made the following trade(s):
- On Wednesday, December 20th, Stonepine Capital, L.P. acquired 45,434 shares of Apollo Endosurgery stock. The shares were bought at an average cost of $4.50 per share, with a total value of $204,453.00.
- On Friday, December 22nd, Stonepine Capital, L.P. acquired 185,157 shares of Apollo Endosurgery stock. The shares were bought at an average cost of $4.85 per share, with a total value of $898,011.45.
Apollo Endosurgery, Inc. (NASDAQ:APEN) traded up $0.13 on Thursday, hitting $5.60. 77,879 shares of the company’s stock traded hands, compared to its average volume of 100,586. Apollo Endosurgery, Inc. has a twelve month low of $3.55 and a twelve month high of $21.88. The company has a market cap of $91.12, a P/E ratio of -0.26 and a beta of 0.46. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.54 and a quick ratio of 2.00.
APEN has been the subject of several research reports. Northland Securities reissued a “buy” rating and set a $12.00 price objective on shares of Apollo Endosurgery in a report on Monday, December 4th. Zacks Investment Research raised shares of Apollo Endosurgery from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a report on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $9.44.
WARNING: This news story was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/12/28/stonepine-capital-l-p-buys-5287-shares-of-apollo-endosurgery-inc-apen-stock.html.
Apollo Endosurgery Company Profile
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.